Payment overview · 2025
General Payments
$605.06
22 reported records · 8 companies
Healthcare provider profile · identity verified
Timothy Jayasundera
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NEW YORK, NY · NPI 1811908205
Verified facts
What the public records show
CMS Open Payments records show Timothy Jayasundera received $605.06 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $230.81 | 38.1% | 11 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $178.12 | 29.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $86.78 | 14.3% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.72 | 4.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.42 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.87 | 3.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.37 | 3.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.97 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $605.06 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $178.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.32 | 6 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $45.51 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $41.27 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.22 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
117 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 48 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 21 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 793 | 270 |
| Amlodipine Besylate | Amlodipine Besylate | 791 | 259 |
| Carvedilol | Carvedilol | 769 | 263 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 305 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 254 | 80 |
| Ezetimibe | Ezetimibe | 253 | 92 |
| Hydralazine Hcl | Hydralazine Hcl | 239 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 76 |
| Furosemide | Furosemide | 148 | 62 |
| Omeprazole | Omeprazole | 142 | 63 |
| Farxiga | Dapagliflozin Propanediol | 139 | 48 |
| Metformin Hcl | Metformin Hcl | 134 | 52 |
| Telmisartan | Telmisartan | 132 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 35 |
| Brilinta | Ticagrelor | 117 | 40 |
| Spironolactone | Spironolactone | 113 | 41 |
| Meloxicam | Meloxicam | 111 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 40 |
| Glipizide Er | Glipizide | 87 | 28 |
| Enalapril Maleate | Enalapril Maleate | 82 | 30 |
| Lisinopril | Lisinopril | 76 | 24 |
| Januvia | Sitagliptin Phosphate | 74 | 25 |
| Azithromycin | Azithromycin | 72 | 56 |
| Eliquis | Apixaban | 68 | 21 |
| Losartan Potassium | Losartan Potassium | 68 | 26 |
| Xarelto | Rivaroxaban | 68 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 15 |
| Methylprednisolone | Methylprednisolone | 57 | 47 |
| Gabapentin | Gabapentin | 52 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 51 | 19 |
| Ranolazine Er | Ranolazine | 51 | 14 |
| Entresto | Sacubitril/Valsartan | 48 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 17 |
| Glipizide | Glipizide | 43 | 18 |
| Labetalol Hcl | Labetalol Hcl | 41 | 16 |
| Nifedipine Er | Nifedipine | 41 | 15 |
| Nitroglycerin | Nitroglycerin | 40 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 17 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 14 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Valsartan | Valsartan | 28 | 16 |
| Celecoxib | Celecoxib | 27 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 26 | 12 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $605.06 · 22 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AVVIGO Guidance System, BREZTRI, CAMZYOS, ELIQUIS, FARXIGA, FFRct, LOKELMA, NEXLETOL, OPSUMIT, Repatha, UPTRAVI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error